p53-dependent and -independent functions of the Arf tumor suppressor

Cold Spring Harbor Symposia on Quantitative Biology

Volumn 70, Issue , 2005, Pages 129-137

  Sherr, C J ^a   Bertwistle, D ^a   Den Besten, W ^a   Kuo, M L ^a   Sugimoto, M ^a   Tago, K ^a   Williams, R T ^a   Zindy, F ^a   Roussel, M F ^a  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARF PROTEIN; PROTEIN P53; TRANSCRIPTION FACTOR; GREEN FLUORESCENT PROTEIN;

CANCER CELL; CATALYSIS; CHEMICAL MODIFICATION; CONFERENCE PAPER; EVIDENCE BASED MEDICINE; GENE ACTIVATION; GENE CONTROL; GENE DELETION; GENE EXPRESSION; GENE FUNCTION; GENE MUTATION; GENE SILENCING; HUMAN; NONHUMAN; ONCOGENE; PRIORITY JOURNAL; PROTEIN DNA INTERACTION; PROTEIN INDUCTION; TUMOR SUPPRESSOR GENE; ARTICLE; CANCER EPIDEMIOLOGY; CELL CYCLE ARREST; CELL PROLIFERATION; DOWN REGULATION; GENE FREQUENCY; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; ORGANOGENESIS; PROTEIN EXPRESSION; UPREGULATION;

AMINO ACID SEQUENCE; ANIMALS; CELL AGING; CYCLIN-DEPENDENT KINASE INHIBITOR P16; GENES, P53; HUMANS; MICE; MICE, KNOCKOUT; MICE, TRANSGENIC; MOLECULAR SEQUENCE DATA; SEQUENCE HOMOLOGY, AMINO ACID; SMALL UBIQUITIN-RELATED MODIFIER PROTEINS; TUMOR SUPPRESSOR PROTEIN P14ARF; TUMOR SUPPRESSOR PROTEIN P53; TUMOR SUPPRESSOR PROTEINS;

MAMMALIA;

EID: 33646514141     PISSN: 00917451     EISSN: None     Source Type: Book Series    
DOI: 10.1101/sqb.2005.70.004     Document Type: Conference Paper

References (100)

1. Adams J.M., Harris A.W., Pinkert C.A., Corcoran L.M., Alexander W.S., Cory S., Palmiter R.D., and Brinster R.L. 1985. The c-myc oncogene driven by immunoglobulin enhancers induces lymphoid malignancy in transgenic mice. Nature 318: 533.
2. Artandi S.E., Chang S., Lee S.L., Alson S., Gottlieb G.J., Chin L., and DePinho R.A. 2000. Telomere dysfunction promotes non-reciprocal translocations and epithelial cancers in mice. Nature 406: 573.
3. Aslanian A., Iaquinta P.J., Verona R., and Lees J.A. 2004. Repression of the Arf tumor suppressor by E2F3 is required for normal cell cycle kinetics. Genes Dev. 18: 1413.
4. Ayrault O., Andrique L., Larsen C.J., and Seite P. 2004. Human Arf tumor suppressor specifically interacts with chromatin containing the promoter of rRNA genes. Oncogene 23: 8097.
5. Bartkova J., Horejsi Z., Koed K., Kramer A., Tort F., Zieger K., Guldberg P., Sehested M., Nesland J.M, Lukas C., Orntoft T., Lukas J., and Bartek J. 2005. DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis. Nature 434: 864.
6. Bertwistle D., Sugimoto M., and Sherr C.J. 2004a. Physical and functional interactions of the Arf tumor suppressor protein with nucleophosmin/B23. Mol. Cell. Biol. 24: 985.
7. Arf tumor suppressor protein. Hybrid. Hybrid. 23: 293.
8. Blasco M.A., Lee H.-W., Hande M.P., Samper E., Lansdorp P.M., DePinho R.A, and Greider C.W. 1997. Telomere shortening and tumor formation by mouse cells lacking telomerase RNA. Cell 91: 25.
9. Boggio R., Colombo R., Hay R.T., Draetta G.F., and Chiocca S. 2004. A mechanism for inhibiting the SUMO pathway. Mol. Cell 16: 549.
10. α-acetyl transferase families. Trends Biochem. Sci. 23: 263.
11. Brady S.N., Yu Y., Maggi L.B., Jr., and Weber J.D. 2004. ARF impedes NPM/B23 shuttling in an Mdm2-sensitive tumor suppressor pathway. Mol. Cell. Biol. 24: 9327.
12. Busuttil R.A., Rubio M., Dolle M.E., Campisi J., and Vijg J. 2003. Oxygen accelerates the accumulation of mutations during the senescence and immortalization of murine cells in culture. Aging Cell 2: 287.
13. ARF act in overlapping pathways in cellular immortalization. Nat. Cell Biol. 2: 148.
14. Chen L. and Chen J. 2003. MDM2-ARF complex regulates p53 sumoylation. Oncogene 22: 5348.
15. Colombo R., Boggio R., Seiser C., Draetta G.F., and Chiocca S. 2002. The adenovirus protein Gam1 interferes with sumoylation of histone deacetylase I. EMBO Rep. 3: 1062.
16. Datta A., Nag A., Pan W., Hay N., Gartel A.L., Colamonici O., Mori Y., and Raychaudhuri P. 2004. Myc-ARF (alternative reading frame) interaction inhibits the functions of Myc. J. Biol. Chem. 279: 36698.
17. ARF tumor suppressor. Genes Dev. 12: 2434.
18. Eischen C.M., Weber J.D., Roussel M.F., Sherr C.J., and Cleveland J.L. 1999. Disruption of the ARF-Mdm2-p53 tumor suppressor pathway in Myc-induced lymphomagenesis. Genes Dev. 13: 2658.
19. El-Deiry W.S., Tokino T., Velculescu V.E., Levy D.B., Parsons R., Trent J.M., Lin D., Mercer E., Kinzler K.W., and Vogelstein B. 1993. WAF1, a potential mediator of p53 tumor suppression. Cell 75: 817.
20. Eymin B., Karayan L., Seite P., Brambilla C., Brambilla E., Larsen C.J., and Gazzeri S. 2001. Human ARF binds E2F1 and inhibits its transcriptional activity. Oncogene 20: 1033.
21. Gil J., Bernard D., Martinez D., and Beach D. 2004. Polycomb CBX7 has a unifying role in cellular lifespan. Nat. Cell Biol. 6: 67.
22. Gomez-Roman N., Grandori C., Eisenman R.N., and White R.J. 2003. Direct activation of RNA polymerase III transcription by c-Myc. Nature 421: 290.
23. Grandori C., Gomez-Roman N., Felton-Edkins Z.A., Ngouenet C., Galloway D.A., Eisenman R.N., and White R.J. 2005. c-Myc binds to human ribosomal DNA and stimulates transcription of rRNA genes by RNA polymerase I. Nat. Cell Biol. 7: 311.
24. Harvey D.M. and Levine A.J. 1991. p53 alteration is a common event in the spontaneous immortalization of primary BALB/c murine embryo fibroblasts. Genes Dev. 5: 2375.
25. Hay R.T. 2001. Protein modification by SUMO. Trends Biochem. Sci. 26: 332.
26. Hilgarth R.S., Murphy L.A., Skaggs H.S., Wilkerson D.C., Xing H., and Sarge K.D. 2004. Regulation and function of SUMO modification. J. Biol. Chem. 279: 53899.
27. ARF with Mdm2 inhibits ubiquitin ligase activity of Mdm2 for tumor suppressor p53. EMBO J. 18: 22.
28. Inoue K., Roussel M.F., and Sherr C.J. 1999. Induction of ARF tumor suppressor gene expression and cell cycle arrest by transcription factor DMP1. Proc. Natl. Acad. Sci. 96: 3993.
29. Inoue K., Zindy F., Randle D.H., Rehg J.E., and Sherr C.J. 2001. Dmp1 is haplo-insufficient for tumor suppression and modifies the frequencies of Arf and p53 mutations in Myc-induced lymphomas. Genes Dev. 15: 2934.
30. Inoue K., Wren R., Rehg J.E., Adachi M., Cleveland J.L., Roussel M.F., and Sherr C.J. 2000. Disruption of the ARF transcriptional activator DMP1 facilitates cell immortalization, Ras transformation, and tumorigenesis. Genes Dev. 14: 1797.
31. Jacks T., Remington L., Williams B.O., Schmitt E.M., Halachmi S., Bronson R.T., and Weinberg R.A. 1994. Tumor spectrum analysis in p53-mutant mice. Curr. Biol. 4: 1.
32. Jacobs J.J.L., Kieboom K., Marino S., DePinho R.A., and van Lohuizen M. 1999a. The oncogene and Polycomb-group gene bmi-1 regulates cell proliferation and senescence through the ink4a locus. Nature 397: 164.
33. Jacobs J.J.L., Scheijen B., Vonchen J.-W., Kieboom K., Berns A., and van Lohuizen M. 1999b. Bmi-1 collaborates with c-Myc in tumorigenesis by inhibiting c-Myc induced apoptosis via INK4a/ARF. Genes Dev. 13: 2678.
34. ARF) and is amplified in a subset of human breast cancers. Nat. Genet. 26: 291.
35. Jerome-Majewska L.A., Jenkins G.P., Ernstoff E., Zindy F., Scherr C. J., and Papaioannou V.E. 2005. Tbx3, the ulnar-mammary syndrome gene, and Tbx2 interact in mammary gland development through a p19Arf/p53-independent pathway. Dev. Dynamics (in press).
36. Johnson E.S. 2004. Protein modification by SUMO. Annu. Rev. Biochem. 73: 355.
37. Johnson E.S. and Gupta A.A. 2001. An E3-like factor that promotes SUMO conjugation to the yeast septins. Cell 106: 735.
38. Kamijo T., Bodner S., van de Kamp E., Randle D.H., and Sherr C.J. 1999a. Tumor spectrum in ARF-deficient mice. Cancer Res. 59: 2217.
39. Kamijo T., van de Kamp E., Chong M.J., Zindy F., Diehl A.J., Sherr C.J., and McKinnon P. 1999b. Loss of the ARF tumor suppressor reverses premature replicative arrest but not radiation hypersensitivity arising from disabled Atm function. Cancer Res. 59: 2464.
40. ARF. Cell 91: 649.
41. Arf suppresses growth, progression, and metastasis of Hras-driven carcinomas through p53-dependent and -independent pathways. PLoS Biol. 2: 1138.
42. Kim S.H., Mitchell M., Fujii H., Llanos S., and Peters G. 2003. Absence of p16INK4a and truncation of ARF tumor suppressors in chickens. Proc. Natl. Acad. Sci. 100: 211.
43. Korgaonkar C., Hagen J., Tompkins V., Frazier A.A., Allamargot C., Quelle F.W., and Quelle D.E. 2005. Nucleophosmin (B23) targets ARF to nucleoli and inhibits its function. Mol. Cell. Biol. 25: 1258.
44. Ink4a confers susceptibility to metastatic melanoma in mice. Nature 413: 83.
45. Kuo M.-L., den Besten W., Bertwistle D., Roussel M.F., and Sherr C.J. 2004. N-terminal polyubiquitination and degradation of the Arf tumor suppressor. Genes Dev. 18: 1862.
46. Latres E., Malumbres M., Sotillo R., Martin J., Ortega S., Martin-Caballero J., Flores J.M., Cordon-Cardo C., and Barbacid M. 2000. Limited overlapping roles of P15(INK4b) and P18(INK4c) cell cycle inhibitors in proliferation and tumorigenesis. EMBO J. 19: 3496.
47. Lee H.-W., Blasco M.A., Gottlieb G.J., Horber J.W., Greider C.W., and DePinho R.A. 1998. Essential role of mouse telomerase in highly proliferative organs. Nature 392: 569.
48. Lingbeek T., Jacobs J.J., and van Lohuizen M. 2002. The T-box repressors TBX2 and TBX3 specifically regulate the tumor suppressor gene p14ARF via a variant T-site in the initiator. J. Biol. Chem. 277: 26120.
49. Llanos S., Clark P.A., Rowe J., and Peters G. 2001. Stabilization of p53 by p14ARF without relocation of MDM2 to the nucleolus. Nat. Cell Biol. 3: 445.
50. Lowe S.W. and Sherr C.J. 2003. Tumor suppression by Ink4a-Arf: Progress and puzzles. Curr. Opin. Genet. Dev. 13: 77.
51. Maeda T., Hobbs R.M., Merghoub T., Guernah I., Zelent A., Cordon-Cardo C., Teruya-Feldstein J., and Pandolfi P.P. 2005. Role of the proto-oncogene Pokemon in cellular transformation and ARF repression. Nature 433: 278.
52. Maestro R., Dei Tos A.P., Hamamori Y., Krasnokutsky S., Sartorelli V., Kedes L., Doglioni C., Beach D., and Hannon G.J. 1999. Twist is a potential oncogene that inhibits apoptosis. Genes Dev. 13: 2207.
53. Martelli F., Hamilton T., Silver D.P., Sharpless N.E., Bardeesy N., Rokas M., DePinho R.A., Livingston D.M., and Grossman S.R. 2001. p19ARF targets certain E2F species for degradation. Proc. Natl. Acad. Sci. 98: 4455.
54. McKeller R.N., Fowler J.L., Cunningham J.J., Warner N., Smeyne R.J., Zindy F., and Skapek S.X. 2002. The Arf tumor suppressor gene promotes hyaloid vascular regression during mouse eye development. Proc. Natl. Acad. Sci. 99: 3848.
55. Melchior F. 2000. SUMO - Nonclassical ubiquitin. Annu. Rev. Cell Dev. Biol. 16: 591.
56. Modestou M., Puig-Antich V., Korgaonkar C., Eapen A., and Quelle D.E. 2001. The alternative reading frame tumor suppressor inhibits growth through p21-dependent and p21-independent pathways. Cancer Res. 61: 3145.
57. Orian A., van Steensel B., Delrow J., Bussemaker H.J., Li L., Sawado T., Williams E., Loo L.W., Cowley S.M., Yost C., Pierce S., Edgar B.A, Parkhurst S.M., and Eisenman R.N. 2003. Genomic binding by the Drosophila Myc, Max, Mad/Mnt transcription factor network. Genes Dev. 17: 1101.
58. Ortega S., Malumbres M., and Barbacid M. 2002. Cyclin D-dependent kinases, INK4 inhibitors, and cancer. Biochim. Biophys. Acta 1602: 73.
59. ARF links the tumour suppressor p53 to Ras. Nature 395: 125.
60. Pantoja C. and Serrano M. 1999. Murine fibroblasts lacking p21 undergo senescence and are resistant to transformation by oncogenic Ras. Oncogene 18: 4974.
61. Parrinello S., Samper E., Krtolica A., Goldstein J., Melov S., and Campisi J. 2003. Oxygen sensitivity severely limits the replicative lifespan of murine fibroblasts. Nat. Cell Biol. 5: 741.
62. Pichler A., Gast A., Seeler J.S., Dejean A., and Melchior F. 2002. The nucleoporin RanBP2 has a SUMO1 E3 ligase activity. Cell 108: 109.
63. Polevoda B. and Sherman F. 2003. N-terminal acetyltransferases and sequence requirements for N-terminal acetylation of eukaryotic proteins. J. Mol. Biol. 325: 595.
64. Qi Y., Gregory M.A., Li Z., Brousal J.P., West K., and Hann S.R. 2004. p19ARF directly and differentially controls the functions of c-Myc independently of p53. Nature 431: 712.
65. Quelle D.E., Cheng M., Ashmun R.A., and Sherr C.J. 1997. Cancer-associated mutations at the INK4a locus cancel cell cycle arrest by p16INK4a but not by the alternative reading frame protein p19ARF. Proc. Natl. Acad. Sci. 94: 669.
66. Quelle, D.E., Zindy F., Ashmun R.A., and Sherr C.J. 1995. Alternative reading frames of the INK4a tumor suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest. Cell 83: 993.
67. Ink4a loss on senescence of murine bone marrow-derived pre-B cells and macrophages. Proc. Natl. Acad. Sci. 98: 9654.
68. Rizos H., Woodruff S., and Kelford R.F. 2005. p14ARF interacts with the SUMO-conjugating enzyme Ubc9 and promotes the sumoylation of its binding partners. Cell Cycle 4: e39.
69. Rocha S., Campbell K.J., and Perkins N.D. 2003. p53- and Mdm2-independent repression of NF-κB transactivation by the ARF tumor suppressor. Mol. Cell 12: 15.
70. Rocha S., Garrett M.D., Campbell K.J., Schumm K., and Perkins N.D. 2005. Regulation of NF-κB and p53 through activation of ATR and Chk1 by the ARF tumour suppressor. EMBO J. 24: 1157.
71. Roussel M.F. 1999. The INK4 family of cell cycle inhibitors in cancer. Oncogene 18: 5311.
72. ARF/p53-induced proliferative arrest. Cancer Cell 2: 55.
73. INK4a/CDKN2A tumor suppressor and its relatives. Biochim Biophys. Acta 1378: F115.
74. Rudolph K.L., Chang S., Lee H.W., Blasco M., Gottlieb G.J., Greider C., and DePinho R.A. 1999. Longevity, stress response, and cancer in aging telomerase-deficient mice. Cell 96: 701.
75. Sachdev S., Bruhn L., Sieber H., Pichler A., Melchior F., and Grosschedl R. 2001. PIASy, a nuclear matrix-associated SUMO E3 ligase, represses LEF1 activity by sequestration into nuclear bodies. Genes Dev. 15: 3088.
76. Schmitt C.A., McCurrach M.E., De Stanchina E., and Lowe S.W. 1999. INK4a/ARF mutations accelerate lymphomagenesis and promote chemoresistance by disabling p53. Genes Dev. 13: 2670.
77. Serrano M., Hannon G.J., and Beach D. 1993. A new regulatory motif in cell cycle control causing specific inhibition of cyclin D/CDK4. Nature 366: 704.
78. Serrano M., Lee H.-W., Chin L., Cordon-Cardo C., Beach D., and DePinho R.A. 1996. Role of the INK4a locus in tumor suppression and cell mortality. Cell 85: 27.
79. Arf predisposes mice to tumorigenesis. Nature 413: 86.
80. Sherr C.J. 1998. Tumor surveillance via the ARF-p53 pathway. Genes Dev. 12: 2984.
81. Sherr C.J. and DePinho R.A. 2001. Cellular senescence: Mitotic clock or culture shock. Cell 102: 407.
82. Shiio Y. and Eisenman R.N. 2003. Histone sumoylation is associated with transcriptional repression. Proc. Natl. Acad. Sci. 100: 13118.
83. Smogorzewska A. and De Lange T. 2002. Different telomere damage signaling pathways in human and mouse cells. EMBO J. 21: 4338.
84. Sreeramaneni R., Chaudhry A., McMahon M., Sherr C.J., and Inoue K. 2005. Ras-Raf-Arf signaling critically depends on the Dmp1 transcription factor. Mol. Cell. Biol. 25: 220.
85. Sugimoto M., Kuo M.L., Roussel M.F., and Sherr C.J. 2003. Nucleolar Arf tumor suppressor inhibits ribosomal RNA processing. Mol. Cell 11: 415.
86. Tago K., Chiocca S., and Sherr C.J. 2005. Sumoylation induced by the Arf tumor suppressor: A p53-independent function. Proc. Natl. Acad. Sci. 102: 7689.
87. Vafa O., Wade M., Kern S., Beeche M., Pandita T.K., Hampton G.M., and Wahl G.M. 2002. c-Myc can induce DNA damage, increase reactive oxygen species, and mitigate p53 function: A mechanism for oncogene-induced genetic instability. Mol. Cell 9: 1031.
88. Vousden K.H. and Lu X. 2002. Live or let die: The cell's response to p53. Nat. Rev. Cancer 2: 594.
89. Weber J.D., Taylor L.J., Roussel M.F., Sherr C.J., and Bar-Sagi D. 1999. Nucleolar Arf sequesters Mdm2 and activates p53. Nat. Cell Biol. 1: 20.
90. Weber J.D., Kuo M.-L., Bothner B., DiGiammarino E.L., Kriwacki R.W., Roussel M.F., and Sherr C.J. 2000a. Cooperative signals governing ARF-Mdm2 interaction and nucleolar localization of the complex. Mol. Cell. Biol. 20: 2517.
91. ARF tumor suppressor. Genes Dev. 14: 2358.
92. Weitzman J.B., Fiette L., Matsuo K., and Yaniv M. 2000. JunD protects cells from p53-dependent senescence and apoptosis. Mol. Cell 6: 1109.
93. Woods Y.L., Xirodimas D.P., Prescott A.R., Sparks A., Lane D.P., and Saville M.K. 2004. p14ARF promotes small ubiquitin-like modifier conjugation of Werners helicase. J. Biol. Chem. 279: 50157.
94. Wright W.E. and Shay J.W. 2000. Telomere dynamics in cancer progression and prevention: Fundamental differences in human and mouse telomere biology. Nat. Med. 6: 849.
95. Xirodimas D.P., Chisholm J., Desterro J.M.S., Lane D.P., and Hay R.T. 2002. p14ARF promotes accumulation of SUMO-1 conjugated (H)Mdm2. FEBS Lett. 528: 207.
96. Zhang Y. and Xiong Y. 1999. Mutations in human ARF exon 2 disrupt its nucleolar localization and impair its ability to block nuclear export of MDM2 and p53. Mol. Cell 3: 579.
97. Zhao L., Samuels T., Winckler S., Korgaonkar C., Tompkins V., Horne M.C, and Quelle D.E. 2003. Cyclin G1 has growth inhibitory activity linked to the ARF-Mdm2-p53 and pRb tumor suppressor pathways. Mol. Cancer Res. 1: 195.
98. INK4a tumor suppressor versus other INK4 family members during mouse development and aging. Oncogene 15: 203.
99. Zindy F., Eischen C.M., Randle D.H., Kamijo T., Cleveland J.L., Sherr C.J., and Roussel M.F. 1998. Myc signaling via the ARF tumor suppressor regulates p53-dependent apoptosis and immortalization. Genes Dev. 12: 2424.
100. Zindy F., Williams R.T., Baudino T.A., Rehg J.E, Skapek S.X., Cleveland J.L., Roussel M.F., and Sherr C.J. 2003. Arf tumor suppressor promoter monitors latent oncogenic signals in vivo. Proc. Natl. Acad. Sci. 100: 15930.